N/A N=149 The Relationship Between Vitamin D and Hepatitis B Virus Replication
Vitamin D and Hepatitis B Virus
Primary: The Dynamic Change of HBV DNA — 3.15; 3.14 IU/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=21 Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection
Hepatitis B
Primary: Change of Serum Hepatitis B Surface Antigen (HBsAg as Measured in log10 IU/mL) Level as an Indicator of Antiviral Activity of Ledipasvir and/or Sofosbuvir in Subjects…
N/A N=203 The Impact of Vitamin D on Tuberculosis Among Koreans
Tuberculosis
Primary: Prevalence of Vitamin D Deficiency — 36.2; 27.3 participants, %
Phase 1 N=20 Hepatitis B Vaccine in Chronic Hepatitis B Patients With Low Serum HBsAg
Chronic Hepatitis B
Primary: Change in HBsAg Levels From Baseline to 2 Years — -0.27 log IU/ml — p=<0.05
Phase 4 N=182 Immunogenicity of Hepatitis B Vaccination in HIV-infected Adults
Hepatitis B Vaccine
Primary: Number and Percentage of Participants With Anti-HBs Seroconversion at Month 7 — 75; 69 Participants
Phase 2 N=16 Adefovir Plus Vaccination in Transplant Patients Without Hepatitis B That Receive a Core Antibody Positive Liver
Hepatitis B · Liver Transplantation
Primary: Development of de Novo Hepatitis B Infection After Transplant With a Core Antibody Positive Liver — 5 Participants
Phase 4 N=480 Immunogenicity of Hepatitis B Vaccination Among Drug Users
Hepatitis B Vaccination
Primary: Number and Rate of Participants With Anti-HBs Seroconversion at Month 7 — 142; 138; 0 Participants
N/A N=82 A Prospective Study of HBV Immunity and HBV Vaccination in Patients With NAFLD in Canada
Non-Alcoholic Fatty Liver Disease · Hepatitis B · Vaccine Reaction
Primary: Anti-HBs Titres (IU/L) — 642; 385 Anti-HBS IU/L — p=0.02
Phase 2 N=13 Pegylated Interferon to Treat Chronic Hepatitis D
Hepatitis D
Primary: Histological Response at 3 Years — 6 participants
Phase 2 N=85 Vitamin D HIV Study on Postmenopausal Women
HIV
Primary: Change in Bone Mineral Density (BMD) — 0.4; -0.8 percentage change
Phase 4 N=10 The Effect of High Dose Vitamin C on the Liver Function in Chronic Hepatitis Patients
Chronic Hepatitis · Chronic Hepatitis C · Chronic Alcoholic Hepatitis
Primary: The Change in Serum Alanine Aminotransferase Level From Baseline to 12 Weeks — 77.5; 105.5 IU/L
Phase 4 N=352 Immunogenicity of Hepatitis B Vaccination in Hemodialysis Patients
Hepatitis B Vaccine
Primary: Anti-HBs Seroconversion Rate at Month 7 — 118; 132 Participants
Phase 2 N=378 Therapeutic Hepatitis B Vaccine (Mimogen-based) Joint Entecavir in Treating Chronic Hepatitis B Patients
Chronic Hepatitis B
Primary: Percentage of Participants With HBeAg Seroconversion at Week 48 — 21; 23 Participants
Phase 2 N=41 Lamivudine and Adefovir to Treat Chronic Hepatitis B
HBV (Hepatitis B Virus) · Hepatitis B · Hepatitis
Primary: Maintained Combined Response (Virological, Biochemical and Histological Response). — 15; 6; 7; 13 participants — p=0.0294
N/A N=743 Prevalence of HBV in Pregnant Women Attending Antenatal Care in Tanzania
Hepatitis B
Primary: HBsAG Prevalence — 22 Participants
Phase 2 N=44 Vitamin D Dose Finding Study
HIV Infections · AIDS
Primary: Safety — 0; 0 participants
Phase 2 N=14 Lonafarnib for Chronic Hepatitis D
Hepatitis D
Primary: Change in Quantitative Serum HDV RNA Levels After 28 Days of Lonafarnib Therapy. — -0.13; -0.73; -1.54 log(IU/ml) — p=0.03
N/A N=122 Vitamin D in HIV-Infected Patients on HAART
Vitamin D Deficiency · HIV
Primary: Success Rate in Achieving a 25(OH)D Level ≥30ng/mL After 12 Weeks of Oral Vitamin D Supplementation. — 81 percentage of participants — p=<0.05
Phase 2 N=13 Add-on Peginterferon Following Nucleos(t)Ide Analogue Treatment
Chronic Hepatitis B
Primary: Change in Interferon-stimulated-gene (ISG) Expression — -2.716; 1.670; -2.20; -1.597 log 2 fold change
Phase 3 N=48 Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D Co-infection (Study P04603)
Hepatitis D, Chronic · Hepatitis B, Chronic
Primary: Number of Participants With a Virological Response — 12; 24; 9; 27 Participants
N/A N=62 Vitamin D Supplements for HIV-positive Patients on cART
HIV-associated Co-morbidities
Primary: 25(OH)D Levels — 13; 20 Participants
N/A N=382 Chronic HBV Management for Asian American
Hepatitis B, Chronic
Primary: Adherence to Recommended HBV Monitoring: Doctor's Visits — 159; 100; 170; 147 Participants
N/A N=145 The Effect of Viral Load on Intrahepatic Recurrence in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC)
Carcinoma, Hepatocellular · Chronic Hepatitis B
Primary: 1,3,5 Year-Disease Free Survival (or Recurrence Free Survival) — 11; 13; 25; 34 participants
Phase 4 N=17 Effect of Omega-3 Fatty Acid on Vitamin D Activation
Hemodialysis Patients · Vitamin D Insufficiency · Vitamin D Deficiency
Primary: 25-hydroxyvitamin D Levels at 12 Weeks — 44.4; 48.9 ng/ml
Phase 2 N=57 Vitamin D3 in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus · SLE · Lupus
Primary: Percent of Participants With an IFN Alpha Signature Response at Week 12 — 36.8; 23.5; 27.8; 25.7 Percent of participants — p=0.53
Phase 3 N=277 Hepatitis B Vaccine Predialysis/Dialysis Study (V232-060)
Hepatitis B Virus Infection
Primary: The Number of Seroprotected Participants to the Modified Process Hepatitis B Vaccine and ENGERIX-B™ (Currently Licensed Vaccine) at Month 7 — 49; 64 Participants
Phase 2 N=55 Supplementation With Cholecalciferol in Dialysis Patients
Chronic Kidney Disease
Primary: Change From Baseline in Interleukin-6 at 12 Weeks. — 9.0; 8.1; 9.6; 4.6 pg/mL
Phase 3 N=204 Hepatitis B Challenge Dose in Adults (V232-059-10)
Hepatitis B
Primary: Percentage of Seroresponders Before and After the Challenge Vaccination — 45.5; 58.8; 85.2; 88.3 Percentage of participants
Phase 4 N=76 Immune Response to Hepatitis B Vaccine Challenge Dose in Subjects Who Received a Primary Neonatal Hepatitis B Vaccine.
Hepatitis B
Primary: Number of Participants With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Above Specific Cut-off Values — 72; 71; 64 participants
N/A N=96 Impact of Vitamin D Repletion in Hemodialysis Patients
Vitamin D Deficiency · End-stage Renal Disease
Primary: Change in 25OH-Vitamin D Level — 15.8; 40.9 ng/dL